Baidu
map

亚盛药业的Bcl-2抑制剂APG-2575用于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤的Ib/II期临床,获得NMPA的批准

2020-04-08 MedSci原创 MedSci原创

亚盛药业(Ascentage Pharma)宣布已获得中国国家药品监督管理局(NMPA)的批准,开展其新型Bcl-2选择性抑制剂APG-2575的Ib/II期研究,治疗复发/难治性慢性淋巴细胞白血病或

亚盛药业(Ascentage Pharma)宣布已获得中国国家药品监督管理局(NMPA)的批准,开展其新型Bcl-2选择性抑制剂APG-2575的Ib/II期研究,治疗复发/难治性慢性淋巴细胞白血病或小淋巴细胞淋巴瘤(r/r CLL/SLL)。

这项开放标签的Ib/II期剂量递增和剂量扩展研究旨在评估APG-2575作为单一药物或联合疗法治疗r/r CLL/SLL患者的安全性、耐受性和初步抗癌活性。

APG-2575是由亚盛药业开发的新型口服Bcl-2选择性抑制剂,通过选择性阻断Bcl-2来恢复癌细胞中的正常凋亡过程,从而治疗多种血液系统恶性肿瘤。

最近的研究表明,Bcl-2抑制剂可有效治疗CLL/SLL,Bcl-2抑制剂与Bruton酪氨酸激酶抑制剂或CD20单克隆抗体联用可提高患者应答并延长患者生存期。先前在美国、澳大利亚和中国开展的APG-2575单一疗法的I期研究显示出良好的安全性和抗癌活性,初步数据支持了APG-2575的持续临床研究。

CLL/SLL是由成熟的B细胞肿瘤引起的血液学恶性肿瘤,主要影响中老年人群。该疾病的特征是癌性淋巴细胞在外周血、骨髓、脾脏和淋巴结中蓄积。随着中国人口的老龄化以及饮食和生活方式的改变,CLL/SLL的发病率一直在增加。

原始出处:

https://www.firstwordpharma.com/node/1713776?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1634986, encodeId=7c0d1634986c6, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Wed Oct 28 00:29:35 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653009, encodeId=c4561653009fe, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Jun 11 15:29:35 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852325, encodeId=f19f1852325a0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Jul 05 08:29:35 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707325, encodeId=91fb1e0732557, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Tue Nov 03 06:29:35 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773142, encodeId=46af1e7314200, content=<a href='/topic/show?id=3ea83260c5' target=_blank style='color:#2F92EE;'>#Bcl-2抑制剂APG-2575#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3260, encryptionId=3ea83260c5, topicName=Bcl-2抑制剂APG-2575)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa1038497429, createdName=minzju5065, createdTime=Thu Aug 20 21:29:35 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995593, encodeId=98ef199559376, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Wed Oct 07 22:29:35 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997980, encodeId=a567199e98013, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Mar 15 23:29:35 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797923, encodeId=d1fa1e9792347, content=<a href='/topic/show?id=fae42429025' target=_blank style='color:#2F92EE;'>#亚盛药业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24290, encryptionId=fae42429025, topicName=亚盛药业)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Sat Sep 05 18:29:35 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702625, encodeId=11151e0262545, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed Apr 29 14:29:35 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302311, encodeId=72231302311b4, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Apr 10 01:29:35 CST 2020, time=2020-04-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1634986, encodeId=7c0d1634986c6, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Wed Oct 28 00:29:35 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653009, encodeId=c4561653009fe, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Jun 11 15:29:35 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852325, encodeId=f19f1852325a0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Jul 05 08:29:35 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707325, encodeId=91fb1e0732557, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Tue Nov 03 06:29:35 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773142, encodeId=46af1e7314200, content=<a href='/topic/show?id=3ea83260c5' target=_blank style='color:#2F92EE;'>#Bcl-2抑制剂APG-2575#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3260, encryptionId=3ea83260c5, topicName=Bcl-2抑制剂APG-2575)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa1038497429, createdName=minzju5065, createdTime=Thu Aug 20 21:29:35 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995593, encodeId=98ef199559376, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Wed Oct 07 22:29:35 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997980, encodeId=a567199e98013, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Mar 15 23:29:35 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797923, encodeId=d1fa1e9792347, content=<a href='/topic/show?id=fae42429025' target=_blank style='color:#2F92EE;'>#亚盛药业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24290, encryptionId=fae42429025, topicName=亚盛药业)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Sat Sep 05 18:29:35 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702625, encodeId=11151e0262545, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed Apr 29 14:29:35 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302311, encodeId=72231302311b4, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Apr 10 01:29:35 CST 2020, time=2020-04-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1634986, encodeId=7c0d1634986c6, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Wed Oct 28 00:29:35 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653009, encodeId=c4561653009fe, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Jun 11 15:29:35 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852325, encodeId=f19f1852325a0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Jul 05 08:29:35 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707325, encodeId=91fb1e0732557, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Tue Nov 03 06:29:35 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773142, encodeId=46af1e7314200, content=<a href='/topic/show?id=3ea83260c5' target=_blank style='color:#2F92EE;'>#Bcl-2抑制剂APG-2575#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3260, encryptionId=3ea83260c5, topicName=Bcl-2抑制剂APG-2575)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa1038497429, createdName=minzju5065, createdTime=Thu Aug 20 21:29:35 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995593, encodeId=98ef199559376, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Wed Oct 07 22:29:35 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997980, encodeId=a567199e98013, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Mar 15 23:29:35 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797923, encodeId=d1fa1e9792347, content=<a href='/topic/show?id=fae42429025' target=_blank style='color:#2F92EE;'>#亚盛药业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24290, encryptionId=fae42429025, topicName=亚盛药业)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Sat Sep 05 18:29:35 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702625, encodeId=11151e0262545, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed Apr 29 14:29:35 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302311, encodeId=72231302311b4, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Apr 10 01:29:35 CST 2020, time=2020-04-10, status=1, ipAttribution=)]
    2020-07-05 jklm09
  4. [GetPortalCommentsPageByObjectIdResponse(id=1634986, encodeId=7c0d1634986c6, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Wed Oct 28 00:29:35 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653009, encodeId=c4561653009fe, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Jun 11 15:29:35 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852325, encodeId=f19f1852325a0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Jul 05 08:29:35 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707325, encodeId=91fb1e0732557, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Tue Nov 03 06:29:35 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773142, encodeId=46af1e7314200, content=<a href='/topic/show?id=3ea83260c5' target=_blank style='color:#2F92EE;'>#Bcl-2抑制剂APG-2575#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3260, encryptionId=3ea83260c5, topicName=Bcl-2抑制剂APG-2575)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa1038497429, createdName=minzju5065, createdTime=Thu Aug 20 21:29:35 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995593, encodeId=98ef199559376, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Wed Oct 07 22:29:35 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997980, encodeId=a567199e98013, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Mar 15 23:29:35 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797923, encodeId=d1fa1e9792347, content=<a href='/topic/show?id=fae42429025' target=_blank style='color:#2F92EE;'>#亚盛药业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24290, encryptionId=fae42429025, topicName=亚盛药业)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Sat Sep 05 18:29:35 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702625, encodeId=11151e0262545, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed Apr 29 14:29:35 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302311, encodeId=72231302311b4, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Apr 10 01:29:35 CST 2020, time=2020-04-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1634986, encodeId=7c0d1634986c6, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Wed Oct 28 00:29:35 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653009, encodeId=c4561653009fe, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Jun 11 15:29:35 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852325, encodeId=f19f1852325a0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Jul 05 08:29:35 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707325, encodeId=91fb1e0732557, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Tue Nov 03 06:29:35 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773142, encodeId=46af1e7314200, content=<a href='/topic/show?id=3ea83260c5' target=_blank style='color:#2F92EE;'>#Bcl-2抑制剂APG-2575#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3260, encryptionId=3ea83260c5, topicName=Bcl-2抑制剂APG-2575)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa1038497429, createdName=minzju5065, createdTime=Thu Aug 20 21:29:35 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995593, encodeId=98ef199559376, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Wed Oct 07 22:29:35 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997980, encodeId=a567199e98013, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Mar 15 23:29:35 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797923, encodeId=d1fa1e9792347, content=<a href='/topic/show?id=fae42429025' target=_blank style='color:#2F92EE;'>#亚盛药业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24290, encryptionId=fae42429025, topicName=亚盛药业)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Sat Sep 05 18:29:35 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702625, encodeId=11151e0262545, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed Apr 29 14:29:35 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302311, encodeId=72231302311b4, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Apr 10 01:29:35 CST 2020, time=2020-04-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1634986, encodeId=7c0d1634986c6, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Wed Oct 28 00:29:35 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653009, encodeId=c4561653009fe, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Jun 11 15:29:35 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852325, encodeId=f19f1852325a0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Jul 05 08:29:35 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707325, encodeId=91fb1e0732557, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Tue Nov 03 06:29:35 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773142, encodeId=46af1e7314200, content=<a href='/topic/show?id=3ea83260c5' target=_blank style='color:#2F92EE;'>#Bcl-2抑制剂APG-2575#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3260, encryptionId=3ea83260c5, topicName=Bcl-2抑制剂APG-2575)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa1038497429, createdName=minzju5065, createdTime=Thu Aug 20 21:29:35 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995593, encodeId=98ef199559376, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Wed Oct 07 22:29:35 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997980, encodeId=a567199e98013, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Mar 15 23:29:35 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797923, encodeId=d1fa1e9792347, content=<a href='/topic/show?id=fae42429025' target=_blank style='color:#2F92EE;'>#亚盛药业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24290, encryptionId=fae42429025, topicName=亚盛药业)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Sat Sep 05 18:29:35 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702625, encodeId=11151e0262545, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed Apr 29 14:29:35 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302311, encodeId=72231302311b4, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Apr 10 01:29:35 CST 2020, time=2020-04-10, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1634986, encodeId=7c0d1634986c6, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Wed Oct 28 00:29:35 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653009, encodeId=c4561653009fe, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Jun 11 15:29:35 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852325, encodeId=f19f1852325a0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Jul 05 08:29:35 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707325, encodeId=91fb1e0732557, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Tue Nov 03 06:29:35 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773142, encodeId=46af1e7314200, content=<a href='/topic/show?id=3ea83260c5' target=_blank style='color:#2F92EE;'>#Bcl-2抑制剂APG-2575#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3260, encryptionId=3ea83260c5, topicName=Bcl-2抑制剂APG-2575)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa1038497429, createdName=minzju5065, createdTime=Thu Aug 20 21:29:35 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995593, encodeId=98ef199559376, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Wed Oct 07 22:29:35 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997980, encodeId=a567199e98013, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Mar 15 23:29:35 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797923, encodeId=d1fa1e9792347, content=<a href='/topic/show?id=fae42429025' target=_blank style='color:#2F92EE;'>#亚盛药业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24290, encryptionId=fae42429025, topicName=亚盛药业)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Sat Sep 05 18:29:35 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702625, encodeId=11151e0262545, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed Apr 29 14:29:35 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302311, encodeId=72231302311b4, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Apr 10 01:29:35 CST 2020, time=2020-04-10, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1634986, encodeId=7c0d1634986c6, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Wed Oct 28 00:29:35 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653009, encodeId=c4561653009fe, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Jun 11 15:29:35 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852325, encodeId=f19f1852325a0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Jul 05 08:29:35 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707325, encodeId=91fb1e0732557, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Tue Nov 03 06:29:35 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773142, encodeId=46af1e7314200, content=<a href='/topic/show?id=3ea83260c5' target=_blank style='color:#2F92EE;'>#Bcl-2抑制剂APG-2575#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3260, encryptionId=3ea83260c5, topicName=Bcl-2抑制剂APG-2575)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa1038497429, createdName=minzju5065, createdTime=Thu Aug 20 21:29:35 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995593, encodeId=98ef199559376, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Wed Oct 07 22:29:35 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997980, encodeId=a567199e98013, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Mar 15 23:29:35 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797923, encodeId=d1fa1e9792347, content=<a href='/topic/show?id=fae42429025' target=_blank style='color:#2F92EE;'>#亚盛药业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24290, encryptionId=fae42429025, topicName=亚盛药业)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Sat Sep 05 18:29:35 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702625, encodeId=11151e0262545, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed Apr 29 14:29:35 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302311, encodeId=72231302311b4, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Apr 10 01:29:35 CST 2020, time=2020-04-10, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1634986, encodeId=7c0d1634986c6, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Wed Oct 28 00:29:35 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653009, encodeId=c4561653009fe, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Jun 11 15:29:35 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852325, encodeId=f19f1852325a0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Jul 05 08:29:35 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707325, encodeId=91fb1e0732557, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Tue Nov 03 06:29:35 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773142, encodeId=46af1e7314200, content=<a href='/topic/show?id=3ea83260c5' target=_blank style='color:#2F92EE;'>#Bcl-2抑制剂APG-2575#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3260, encryptionId=3ea83260c5, topicName=Bcl-2抑制剂APG-2575)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa1038497429, createdName=minzju5065, createdTime=Thu Aug 20 21:29:35 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995593, encodeId=98ef199559376, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Wed Oct 07 22:29:35 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997980, encodeId=a567199e98013, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Mar 15 23:29:35 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797923, encodeId=d1fa1e9792347, content=<a href='/topic/show?id=fae42429025' target=_blank style='color:#2F92EE;'>#亚盛药业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24290, encryptionId=fae42429025, topicName=亚盛药业)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Sat Sep 05 18:29:35 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702625, encodeId=11151e0262545, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed Apr 29 14:29:35 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302311, encodeId=72231302311b4, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Apr 10 01:29:35 CST 2020, time=2020-04-10, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1634986, encodeId=7c0d1634986c6, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Wed Oct 28 00:29:35 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653009, encodeId=c4561653009fe, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Thu Jun 11 15:29:35 CST 2020, time=2020-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852325, encodeId=f19f1852325a0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Jul 05 08:29:35 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707325, encodeId=91fb1e0732557, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Tue Nov 03 06:29:35 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773142, encodeId=46af1e7314200, content=<a href='/topic/show?id=3ea83260c5' target=_blank style='color:#2F92EE;'>#Bcl-2抑制剂APG-2575#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3260, encryptionId=3ea83260c5, topicName=Bcl-2抑制剂APG-2575)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa1038497429, createdName=minzju5065, createdTime=Thu Aug 20 21:29:35 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995593, encodeId=98ef199559376, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Wed Oct 07 22:29:35 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997980, encodeId=a567199e98013, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Mon Mar 15 23:29:35 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797923, encodeId=d1fa1e9792347, content=<a href='/topic/show?id=fae42429025' target=_blank style='color:#2F92EE;'>#亚盛药业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24290, encryptionId=fae42429025, topicName=亚盛药业)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Sat Sep 05 18:29:35 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702625, encodeId=11151e0262545, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Wed Apr 29 14:29:35 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302311, encodeId=72231302311b4, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Fri Apr 10 01:29:35 CST 2020, time=2020-04-10, status=1, ipAttribution=)]

相关资讯

李建勇教授:经典药物焕新春,浅谈慢性淋巴细胞白血病的治疗

2020年1月11-12日,CSCO 抗白血病联盟 & 抗淋巴瘤联盟工作会议暨2020 年白血病·淋巴瘤高峰论坛在深圳隆重召开,国内血液肿瘤领域权威专家汇聚一堂,共同探讨白血病及淋巴瘤热点话题。美罗华 (利妥昔单抗)是淋巴瘤治疗的基石药物,2019年12月,美罗华再获得中国国家药品监督管理总局(NMPA)正式批准,用于初治滤泡性淋巴瘤(FL)患者经利妥昔单抗联合化疗后达完全或部分缓解后的单

BCL-2抑制剂VENCLYXTO与CD20单抗obinutuzumab的联合疗法获欧洲批准,用于未经治疗的慢性淋巴细胞白血病

艾伯维宣布,欧盟委员会已批准将其B细胞淋巴瘤2(BCL-2)抑制剂VENCLYXTO(venetoclax) 与CD20单抗obinutuzumab组合用于以前未经治疗的慢性淋巴细胞性白血病患者。

NCCN临床实践指南:慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(2020.V4)

2019年12月,美国国家综合癌症网络(NCCN)发布了慢性淋巴细胞白血病/小淋巴细胞淋巴瘤指南2020年第4版,指南主要内容涉及: 指南更新摘要 慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的诊断、检查、分期 虚弱患者的严重合并症 没有17p缺失或Tp53突变的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤 17p缺失或Tp53突变的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤 慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的预后

Blood:CD49d促进慢性淋巴细胞白血病进展

中心点:CD49d双峰表达的CLL患者占CLL的20%,表现出截然不同的临床生物学特征。CD49d对预后的影响随着将CD49d双峰表达的纳入而增强。摘要:CD49d是慢性淋巴细胞白血病(CLL)一个显著的预后生物标志物。经过广泛验证的30%的CLL阳性细胞阈值可以将CLL患者分为两个预后不同的亚组,但未考虑到CD49d的表达模式。在本研究中,研究人分析了1630例CLL样本,发现约20%的CLL病

对于未经治疗的慢性淋巴细胞白血病患者,AbbVie的BCL-2抑制剂VENCLYXTO联合CD20单抗获得欧洲人用药物委员会的正面评价

艾伯维公司宣布其BCL-2抑制剂VENCLYXTO(venetoclax)联合CD20单抗obinutuzumab用于先前未经治疗的慢性淋巴细胞白血病(CLL),获得欧洲药品管理局(EMA)人类用药品委员会(CHMP)的积极意见。

2019 ASH:阿斯利康的BTK抑制剂Calquence提高了慢性淋巴细胞白血病患者的无进展生存期

阿斯利康的BTK抑制剂Calquence在一项III期试验中结果显示了该药物对慢性淋巴细胞性白血病(CLL)患者无进展生存期(PFS)的影响。

Baidu
map
Baidu
map
Baidu
map